These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12401238)

  • 1. New leadership for the FDA.
    Lancet; 2002 Oct; 360(9341):1183. PubMed ID: 12401238
    [No Abstract]   [Full Text] [Related]  

  • 2. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA appointee faces angry, demoralized staff.
    Fox JL
    Nat Biotechnol; 2002 Nov; 20(11):1065. PubMed ID: 12410237
    [No Abstract]   [Full Text] [Related]  

  • 5. America's other drug problem: how the drug industry distorts medicine and politics.
    Relman AS; Angell M
    New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
    [No Abstract]   [Full Text] [Related]  

  • 6. User fees for faster drug reviews. Are they helping or hurting the public health?
    Thompson L
    FDA Consum; 2000; 34(5):25-9. PubMed ID: 11590789
    [No Abstract]   [Full Text] [Related]  

  • 7. User fees to fund faster reviews.
    Henkel J
    FDA Consum; 1993 Oct; 27(8):19-21. PubMed ID: 10129049
    [No Abstract]   [Full Text] [Related]  

  • 8. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 9. Changes in FDA drug classification and priority review policy.
    Crawford SY
    Am J Hosp Pharm; 1992 Oct; 49(10):2383, 2386. PubMed ID: 1442812
    [No Abstract]   [Full Text] [Related]  

  • 10. Fifth Annual David A. Winston Lecture.
    McClellan MB
    J Health Adm Educ; 2004; 21(1):3-14. PubMed ID: 15129897
    [No Abstract]   [Full Text] [Related]  

  • 11. HHS: POUFA reauthorization good for Americans.
    FDA Consum; 2002; 36(5):5. PubMed ID: 12412536
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA joins market.
    Gershon D
    Nature; 1993 Jul; 364(6433):93. PubMed ID: 8321293
    [No Abstract]   [Full Text] [Related]  

  • 13. New fee structure proposed by FDA might lead to more talk.
    Waters H
    Nat Med; 2011 Oct; 17(10):1159. PubMed ID: 21988966
    [No Abstract]   [Full Text] [Related]  

  • 14. New drug law to speed scientific review.
    Nature; 1992 Oct; 359(6396):563. PubMed ID: 1406977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. US 21st Century Cures Act secures health-care research funding.
    Furlow B
    Lancet Oncol; 2017 Jan; 18(1):24. PubMed ID: 27979600
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA a main culprit in delayed access to technology.
    Albertson D
    MLO Med Lab Obs; 1995 Aug; 27(8):23-4. PubMed ID: 10144934
    [No Abstract]   [Full Text] [Related]  

  • 17. Will politics sidetrack FDA reform?
    Gatty B
    Formulary; 1995 Aug; 30(8):476, 475. PubMed ID: 10151736
    [No Abstract]   [Full Text] [Related]  

  • 18. A turbulent year at the agency.
    Ratner M
    Nat Biotechnol; 2006 Feb; 24(2):145-51. PubMed ID: 16465153
    [No Abstract]   [Full Text] [Related]  

  • 19. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. User fees to hasten FDA review.
    Gershon D
    Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.